PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
- Conditions
- Metastatic Renal Cell Carcinoma
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77
- Registration Number
- NCT03140176
- Locations
- π©πΏ
Pierre Et Marie Curie Center, Algers, Algeria
π©πΏHanene Djedi, Annaba, Algeria
πͺπ¬Demerdash Hospital, Cairo, Egypt
A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03137134
- Locations
- πΊπΈ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.
- Conditions
- Meningococcal Vaccine
- Interventions
- Biological: rLP2086Biological: MenABCWYBiological: MenACWY-CRMBiological: Saline
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1610
- Registration Number
- NCT03135834
- Locations
- πΊπΈ
Optimal Research, LLC, Melbourne, Florida, United States
πΊπΈCoastal Carolina Research Center, North Charleston, South Carolina, United States
πΊπΈClinical Research Consortium, Tempe, Arizona, United States
A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03130556
- Locations
- πΊπΈ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT03128411
- Locations
- π―π΅
Osaka City University Hospital, Osaka-City, Osaka, Japan
π―π΅Kindai University Hospital, Osaka-Sayama, Osaka, Japan
π―π΅NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan
Inotuzumab Ozogamicin - PF-05208773
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2020-05-18
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03127605
Lorlatinib - PF-06463922
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03127618
The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03126721
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium
First in Human Study for PF-06667272
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT03126149
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium
A Study To Estimate The Effects Of Itraconazole On Pharmacokinetics Of Pf-06649751 In Healthy Adult Subjects
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT03121664
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium